Metastasis-directed therapy (MDT) delivered via stereotactic body radiotherapy has gained substantial attention over the past decade. Landmark trials such as STOMP1 and ORIOLE2 fundamentally shifted the management paradigm for metastatic prostate cancer. These pioneering studies showed improved progression-free survival in patients with up to three metastases compared with observation alone (HR 0·60, 95% CI 0·40–0·90 in STOMP; HR 0·30, 0·11–0·81…
[Comment] Oligometastatic prostate cancer: time to integrate metastasis-directed therapy
The Lancet Oncology | | Simon K B Spohn, Anca-Ligia Grosu
Topics: prostate-cancer, blood-cancer, radiation, clinical-trials, research